JLS Fund

Homecoming is a provider of patient engagement tools tailored for psychedelic therapy. The company has developed a digital companion application that supports patients throughout their healing process. This application promotes accountability and long-term change by offering personalized guides, tasks, and daily check-ins, all within a user-friendly platform. It also facilitates preparation and integration support, enabling healthcare professionals to effectively guide their patients. Homecoming's focus on enhancing the therapeutic experience aims to improve outcomes for individuals undergoing psychedelic therapy.

Fluence provides educational programs focused on psychedelic integration and psychedelic-assisted therapy, aimed at licensed professionals and advanced graduate students. The organization offers continuing education and certification courses that enhance the skills and knowledge of healthcare workers, enabling them to deliver effective and compassionate psychedelic therapy. While there are no specific prerequisites for enrollment, a foundational understanding of the mental health field is beneficial. The programs are interactive, incorporating discussions, demonstrations, self-reflection exercises, and role plays to facilitate learning. Although some classes are exclusively for licensed clinicians, many programs are accessible to a broader audience interested in the subject.

Psilera is focused on developing psychedelics-based drugs aimed at improving neurological health. The company utilizes its expertise in pharmaceutical and cannabis industries to create a robust intellectual property portfolio centered on analogues derived from psychoactive precursors. Psilera formulates and screens lead compounds against various neurological targets to assess their clinical potential, with a pipeline that addresses mood disorders, cognitive diseases, and addiction. By repurposing natural psychoactive products, Psilera seeks to advance next-generation therapies that enhance mental health outcomes, ultimately aiming to alleviate human suffering.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, founded in 2019. The company specializes in developing innovative psychotropic drugs aimed at treating various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Gilgamesh focuses on creating novel chemical entities through a blend of medicinal chemistry, neuroscience, and drug development expertise. By leveraging its unique approach, the company aims to provide effective therapies that enhance recovery for patients dealing with central nervous system disorders.

WeSana Health is a life sciences company that provides advancement of psilocybin-based medicine. The company was founded in 2020 by Daniel Carcillo and is headquartered in Homer Glen, Illinois, United States.